Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 28137908
Davis RJ, Swanger J, Hughes BT, Clurman BE (2017) The PP2A-B56 Phosphatase Opposes Cyclin E Autocatalytic Degradation via Site-Specific Dephosphorylation. Mol Cell Biol 37 28137908
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T77-p - CCNE1 (human)
Modsite: DPCsLIPtPDKEDDD SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): T77‑p, CCNE1 (mouse): T74‑p, CCNE1 (rat): T77‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  HCT116 (intestinal), HEK293-A (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A no change compared to control
seliciclib no change compared to control

T395-p - CCNE1 (human)
Modsite: PLPSGLLtPPQsGKK SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): T395‑p, CCNE1 (mouse): T393‑p, CCNE1 (rat): T396‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  HCT116 (intestinal), HEK293-A (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A no change compared to control
seliciclib no change compared to control

S399-p - CCNE1 (human)
Modsite: GLLtPPQsGKKQSSG SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): S399‑p, CCNE1 (mouse): S397‑p, CCNE1 (rat): S400‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  HCT116 (intestinal), HEK293-A (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PPP2R5C (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2R5C (human) co-immunoprecipitation, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
KINASE CDK1 (human)
Comments:  Autophosphorylation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A increase
seliciclib decrease
Downstream Regulation
Effect of modification (function):  activity, induced, protein degradation
Effect of modification (process):  cell cycle regulation
Comments:  decreased CCNE1 stabilization (abundance)